BMO Capital initiated coverage of IGM Biosciences (IGMS) with an Outperform rating and $21 price target IGM is a clinical-stage biotechnology developing immunoglobulin M antibodies for the treatment of autoimmune and inflammatory diseases, the analyst tells investors in a research note. The firm says imvotamab, a T cell engaging antibody targeting CD20 and CD3 proteins, is currently being evaluated in three Phase 1 clinical trials in autoimmune diseases. BMO sees “significant upside” to IGM shares on “upcoming clinical de-risking.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- JPMorgan healthcare analysts hold an analyst/industry conference call
- IGM Biosciences price target raised to $27 from $25 at Stifel
- Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development
- IGM Biosciences Shifts Focus to Autoimmunity
- IGM Biosciences reports Q3 EPS ($1.01), consensus (80c)